Two Sigma Advisers
WINT

Two Sigma Advisers’s Windtree Therapeutics WINT Stock Holding History

Two Sigma Advisers’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$35K – 2748
2022
Q2 		$35K Hold
2
– – ﹤0.01% 2510
2022
Q1 		$128K Sell
2
-1
-33% -$52.5K ﹤0.01% 2466
2021
Q4 		$219K Buy
+3
New +$240K ﹤0.01% 2258

Other funds holding WINT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $2.66B AUM 26.2% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Two Sigma Advisers's WINT Position: Q3 2022 in Review

Two Sigma Advisers sold out of Windtree Therapeutics (WINT) in Q3 2022, closing a stake of 2 shares — an estimated $35K sold.

Two Sigma Advisers first reported a position in WINT in Q4 2021 and held it in 3 quarters. The position peaked at $219K in Q4 2021. 11 funds tracked by Wall St. Rank hold WINT as of Q3 2022.

  • Two Sigma Advisers reported no remaining Windtree Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 2 Windtree Therapeutics shares in Q3 2022, an estimated $35K.
  • Two Sigma Advisers first reported a position in Windtree Therapeutics in Q4 2021 and held it in 3 quarters.
  • Two Sigma Advisers's Windtree Therapeutics position peaked at $219K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.